149 related articles for article (PubMed ID: 37162567)
1. Intensity-modulated radiotherapy and cisplatin-based chemotherapy for anal cancer: long-term outcomes at a single institution.
Gerardi MA; Zerella MA; Bergamaschi L; Ferrari A; Arculeo S; Bagnardi V; Frassoni S; Petz W; Fodor C; Emiro F; Cattani F; Leonardi MC; Zampino MG; Jereczek-Fossa BA
Int J Colorectal Dis; 2023 May; 38(1):123. PubMed ID: 37162567
[TBL] [Abstract][Full Text] [Related]
2. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
[TBL] [Abstract][Full Text] [Related]
3. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.
Holliday EB; Morris VK; Johnson B; Eng C; Ludmir EB; Das P; Minsky BD; Taniguchi C; Smith GL; Koay EJ; Koong AC; Delclos ME; Skibber JM; Rodriguez-Bigas MA; You YN; Bednarski BK; Tillman MM; Chang GJ; Jennings K; Messick CA
Oncologist; 2022 Feb; 27(1):40-47. PubMed ID: 35305097
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine/cisplatin combined with concurrent intensity-modulated radiation therapy: a feasible therapeutic strategy for anal squamous cell carcinoma.
Li J; Huang C; Wang X; Li Z; Shen Y
Clin Transl Oncol; 2024 Mar; 26(3):739-746. PubMed ID: 37568008
[TBL] [Abstract][Full Text] [Related]
5. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
[TBL] [Abstract][Full Text] [Related]
6. Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Anticancer Res; 2016 Apr; 36(4):2027-32. PubMed ID: 27069197
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
[TBL] [Abstract][Full Text] [Related]
8. Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma.
Untiedt S; Rolf D; Scobioala S; Wolters H; Elsayad K; Oertel M; Kittel C; Pascher A; Rijcken E; Ullerich H; Glasbrenner B; Eich HT
Strahlenther Onkol; 2023 Aug; 199(8):749-760. PubMed ID: 36862155
[TBL] [Abstract][Full Text] [Related]
9. Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience.
Jethwa KR; Day CN; Sandhyavenu H; Gonuguntla K; Harmsen WS; Breen WG; Routman DM; Garda AE; Hubbard JM; Halfdanarson TR; Neben-Wittich MA; Merrell KW; Hallemeier CL; Haddock MG
Clin Transl Radiat Oncol; 2021 May; 28():17-23. PubMed ID: 33732911
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients.
Cho BC; Ahn JB; Seong J; Roh JK; Kim JH; Chung HC; Sohn JH; Kim NK
BMC Cancer; 2008 Jan; 8():8. PubMed ID: 18194582
[TBL] [Abstract][Full Text] [Related]
11. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
[TBL] [Abstract][Full Text] [Related]
12. Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma.
Zampino MG; Magni E; Leonardi MC; Santoro L; Petazzi E; Fodor C; Petralia G; Trovato C; Nolè F; Orecchia R
BMC Cancer; 2011 Feb; 11():55. PubMed ID: 21291546
[TBL] [Abstract][Full Text] [Related]
13. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
[TBL] [Abstract][Full Text] [Related]
14. Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
Julie DA; Oh JH; Apte AP; Deasy JO; Tom A; Wu AJ; Goodman KA
Acta Oncol; 2016; 55(2):208-16. PubMed ID: 25984929
[TBL] [Abstract][Full Text] [Related]
15. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
16. [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Hannoun L; Houry S; Huguet F; Pène F; Parc R; Schlienger M
Cancer Radiother; 2006 Dec; 10(8):572-82. PubMed ID: 17110148
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure.
de Meric de Bellefon M; Lemanski C; Castan F; Samalin E; Mazard T; Lenglet A; Demontoy S; Riou O; Llacer-Moscardo C; Fenoglietto P; Aillères N; Thezenas S; Debrigode C; Vieillot S; Gourgou S; Azria D
Radiother Oncol; 2020 Mar; 144():141-147. PubMed ID: 31809980
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.
Hung A; Crane C; Delclos M; Ballo M; Ajani J; Lin E; Feig B; Skibber J; Janjan N
Cancer; 2003 Mar; 97(5):1195-202. PubMed ID: 12599225
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin/capecitabine with intensity-modulated radiation therapy in anal squamous cell carcinoma: a preliminary study.
Li J; Xu H; Zou J; Wang X; Li Z; Shen Y
Scand J Gastroenterol; 2021 Apr; 56(4):432-436. PubMed ID: 33556252
[TBL] [Abstract][Full Text] [Related]
20. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C
Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
